Article
Hematology
Kelly S. Chien, Christine B. Peterson, Elliana Young, Dai Chihara, Elizabet E. Manasanch, Jeremy L. Ramdial, Philip A. Thompson
Summary: Patients with hematologic malignancies who have been vaccinated against COVID-19 have lower hospitalization rates compared to those who have not been vaccinated, but their rates of COVID-19-associated death are similar. Female, older patients, and individuals with higher comorbidity scores are at higher risk of death from COVID-19 infections. Vaccination is associated with a decreased risk of hospitalization but not with a decreased risk of death from COVID-19 infections. Protective strategies are needed in addition to vaccination for this vulnerable patient population.
Article
Oncology
Thomas A. Ollila, Rebecca H. Masel, John L. Reagan, Shaolei Lu, Ralph D. Rogers, Kimberly J. Paiva, Rashida Taher, Ella Burguera-Couce, Adam S. Zayac, Inna Yakirevich, Rabin Niroula, Peter Barth, Adam J. Olszewski
Summary: Patients with hematologic malignancies have reduced response to COVID-19 vaccination, but booster vaccinations can improve seroconversion rate. Prophylactic antibody therapy can prevent COVID-19 infection and death.
Article
Oncology
Noha Sharafeldin, Benjamin Bates, Qianqian Song, Vithal Madhira, Yao Yan, Sharlene Dong, Eileen Lee, Nathaniel Kuhrt, Yu Raymond Shao, Feifan Liu, Timothy Bergquist, Justin Guinney, Jing Su, Umit Topaloglu
Summary: The largest multicenter cohort of cancer patients with COVID-19 to date was constructed by the U.S. N3C collaboration. It was found that COVID-19 positivity significantly increased the risk of all-cause mortality in cancer patients. Factors such as age, gender, region, comorbidities, and specific cancer types were associated with increased mortality risk in cancer patients with COVID-19.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Xuejun Alice Wang, Adam F. Binder, Usama Gergis, Lindsay Wilde
Summary: This study presents the experience of a single institution with HM patients diagnosed with COVID-19 from March 2020 to March 2021. Among 62 cases reported, 10 patients died with an overall mortality of 16.1%. Findings showed that patients with HM and COVID-19 had various disease severities, with a high proportion having active disease and multiple comorbidities. While some patients were asymptomatic or had mild disease, others required hospitalization and a minority needed ICU level care, with a high mortality rate among those in the ICU.
FRONTIERS IN ONCOLOGY
(2021)
Article
Hematology
Livio Pagano, Jon Salmanton-Garcia, Francesco Marchesi, Ola Blennow, Maria Gomes da Silva, Andreas Glenthoj, Jaap van Doesum, Yavuz M. Bilgin, Alberto Lopez-Garcia, Federico Itri, Raquel Nunes Rodrigues, Barbora Weinbergerova, Francesca Farina, Giulia Dragonetti, Caroline Berg Venemyr, Jens van Praet, Ozren Jaksic, Toni Valkovic, Iker Falces-Romero, Sonia Martin-Perez, Moraima Jimenez, Julio Davila-Valls, Martin Schonlein, Emanuele Ammatuna, Stef Meers, Mario Delia, Zlate Stojanoski, Anna Nordlander, Tobias Lahmer, Laszlo Imre Pinczes, Caterina Buquicchio, Klara Piukovics, Irati Ormazabal-Velez, Nicola Fracchiolla, Michail Samarkos, Gustavo-Adolfo Mendez, Jose-Angel Hernandez-Rivas, Ildefonso Espigado, Martin Cernan, Verena Petzer, Sylvain Lamure, Roberta di Blasi, Joyce Marques de Almedia, Michelina Dargenio, Monika M. Biernat, Mariarita Sciume, Cristina de Ramon, Nick de Jonge, Josip Batinic, Avinash Aujayeb, Monia Marchetti, Guillemette Fouquet, Noemi Fernandez, Giovanni Zambrotta, Maria Vittoria Sacchi, Anna Guidetti, Fatih Demirkan, Lucia Prezioso, Zdenek Racil, Marcio Nucci, Milos Mladenovic, Raphael Lievin, Michaela Hanakova, Stefanie Grafe, Uluhan Sili, Marina Machado, Chiara Cattaneo, Tatjana Adzic-Vukicevic, Luisa Verga, Jorge Labrador, Laman Rahimli, Matteo Bonanni, Francesco Passamonti, Antonio Pagliuca, Paolo Corradini, Martin Hoenigl, Philipp Koehler, Alessandro Busca, Oliver A. Cornely
Summary: Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-SARS-CoV-2 vaccination. This study found a relatively low mortality rate among patients with breakthrough COVID-19, with the Omicron variant being the predominant strain. Patients receiving monoclonal antibody treatment had a lower mortality rate.
Article
Hematology
Katrin Herzog Tzarfati, Odit Gutwein, Arie Apel, Naomi Rahimi-Levene, Maya Sadovnik, Lotem Harel, Patricia Benveniste-Levkovitz, Adina Bar Chaim, Maya Koren-Michowitz
Summary: Patients with hematologic malignancies have a reduced immune response to the COVID-19 vaccine, with lower seropositivity rates and antibody titers, increasing their risk for severe infection.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Medicine, General & Internal
Chien-Tzu Huang, Ching-Ping Lee, Tzu-Yin Chen, Yi-Chang Liu, Shih-Feng Cho, Jeng-Shiun Du, Ming-Lung Yu, Chung-Feng Huang, Sheng-Fan Wang, Hui-Hua Hsiao
Summary: In this prospective study, the serological responses to booster COVID-19 vaccines were evaluated in Taiwanese patients with hematologic malignancies. The majority of patients achieved seroconversion after booster doses, but exhibited reduced effective neutralization compared to healthy individuals. Lack of B-cell-targeted agents and higher immunoglobulin levels were identified as independent predictors for effective neutralization.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Yongkang Liao, Shijun Xiong, Zaid Ur Rehman, Xiaoli He, Hongling Peng, Jing Liu, Shuming Sun
Summary: This review summarizes the research progress of aptamers in the diagnosis and treatment of hematologic malignancies, providing support for the application of aptamers in this field. Aptamer-based targeted therapies have shown promising potential in achieving more targeted goals in hematologic malignancies. The findings of these studies provide multiple approaches for future basic and clinical trials research in this field.
Review
Hematology
Jose Carlos Martinez, R. Alejandro Sica, Keith Stockerl-Goldstein, Samuel M. Rubinstein
Summary: Patients with hematologic malignancies are at higher risk of severe COVID-19 and have worse outcomes compared to patients with solid tumors and the general population. Risk factors include both shared factors with the general population and cancer-specific factors. Emerging evidence suggests that specific treatments such as convalescent plasma and booster doses of COVID-19 vaccines may benefit this patient population.
ACTA HAEMATOLOGICA
(2022)
Review
Hematology
Chaja F. Jacobs, Eric Eldering, Arnon P. Kater
Summary: Tyrosine kinase inhibitors are being explored for use in the treatment of different stages of COVID-19 and other hematologic malignancies, although most studies are done in vitro and may not apply to a wider population. Many in vivo effects reported are based on artificial animal models or symptomatic patients with hematologic malignancies.
Article
Economics
Paresh Kumar Narayan
Summary: This paper surveys the literature on the COVID-19 pandemic, finding that stock market performance, COVID-19 policies, and energy markets are the most researched areas due to the availability of high-frequency time-series data supported by econometric tools. It discusses various socioeconomic and finance-related subjects of significant policy importance, identifying specific and broad areas in need of immediate research, which have strong policy implications.
ECONOMIC ANALYSIS AND POLICY
(2021)
Article
Hematology
Firas El Chaer, Jeffery J. Auletta, Roy F. Chemaly
Summary: Patients with hematologic malignancies and recipients of HCT are at higher risk of severe COVID-19 and have suboptimal response to vaccines. Treatment options should be selected based on host factors, virus factors, and therapeutic considerations.
Review
Biochemistry & Molecular Biology
Ilaria Carola Casetti, Oscar Borsani, Elisa Rumi
Summary: The COVID-19 outbreak has greatly impacted patients with hematologic diseases whose immune systems may be compromised due to treatments. Hematologic malignancies have emerged as a risk factor for severe COVID-19 infection, emphasizing the importance of vaccination for these patients.
Review
Hematology
Petra Langerbeins, Michael Hallek
Summary: COVID-19 exhibits symptomatic heterogeneity and has a significant impact on the immune response of patients with hematologic malignancy. Vaccination against SARS-CoV-2 is important, but the immune response in these patients may be impaired. Antiviral drugs and monoclonal antibodies are available for prevention and treatment of COVID-19, but their efficacy may decrease against new variants.
Review
Hematology
Joanne S. K. Teh, Julien Coussement, Zoe C. F. Neoh, Tim Spelman, Smaro Lazarakis, Monica A. Slavin, Benjamin W. Teh
Summary: This study assessed the immunogenicity and safety of COVID-19 vaccines in patients with hematologic malignancies. The results showed that the seropositivity rates after 2 doses of COVID-19 vaccine were 62% to 66%, and after 1 dose were 37% to 51%. The neutralizing antibody response rates were 57% to 60%, and cellular response rates were 40% to 75%. Active treatment, ongoing or recent treatment with targeted therapies were associated with poor immune responses to COVID-19 vaccine.
Article
Hematology
Joanna Roopkumar, Shyam K. Poudel, Lorenzo Gervaso, Chandana A. Reddy, Vamsidhar Velcheti, Nathan A. Pennell, Keith R. McCrae, Alok A. Khorana
Summary: Patients with ALK-mutant advanced lung adenocarcinoma have the highest rate of TE, which is associated with worse survival across all molecular subtypes. These findings underscore the importance of considering thromboprophylaxis in clinical decision-making.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Editorial Material
Oncology
Nathan A. Pennell
Review
Medicine, General & Internal
Christina Mayerhofer, Charlotte M. Niemeyer, Christian Flotho
Summary: JMML is a rare pediatric leukemia characterized by mutations in RAS pathway genes, with treatment options based on genetic profile and disease severity. Management can include medication or allogeneic hematopoietic stem cell transplantation tailored to individual patient needs.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Hematology
Charlotte M. Niemeyer, Christian Flotho, Daniel B. Lipka, Jan Stary, Claudia Rossig, Andre Baruchel, Thomas Klingebiel, Concetta Micalizzi, Gerard Michel, Karsten Nysom, Susana Rives, Markus Schmugge Liner, Marco Zecca, Maximilian Schoenung, Irith Baumann, Peter Nollke, Bouchra Benettaib, Noha Biserna, Jennifer Poon, Mathew Simcock, Meera Patturajan, Daniel Menezes, Allison Gaudy, Marry M. Van den Heuvel-Eibrink, Franco Locatelli
Summary: Azacitidine monotherapy is a feasible option for children with newly diagnosed JMML, providing valuable clinical benefits prior to HSCT. Long-term safety and efficacy data in this population are still needed for full elucidation.
Letter
Oncology
Vidya Sankar Viswanathan, Mohammadhadi Khorrami, Khalid Jazieh, Pingfu Fu, Nathan Pennell, Anant Madabhushi
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Medical Informatics
Katie N. Dainty, M. Bianca Seaton, Antonio Estacio, Lisa K. Hicks, Trevor Jamieson, Sarah Ward, Catherine H. Yu, Jeffrey D. Mosko, Charles D. Kassardjian
Summary: This study examined the key factors associated with virtual specialist care and found a high level of satisfaction among patients. However, there are still considerations to be made to ensure its sustainability as a standard of care.
JMIR MEDICAL INFORMATICS
(2022)
Review
Oncology
Andrea Anampa-Guzman, Janet Freeman-Daily, Michael Fisch, Emil Lou, Nathan A. Pennell, Corrie A. Painter, Dorinda Sparacio, Mark A. Lewis, Maimah Karmo, Patricia F. Anderson, Stephanie L. Graff
Summary: Patients with cancer use the Internet to gain knowledge about their disease and connect with others facing the same challenges. Online cancer communities have become valuable resources for new research and care pathways. Some patients have become experts in their cancer, playing an important role in advancing cancer medicine. Clinicians, researchers, and others acknowledge the vital input of e-patients in informing cancer care and policy. Expert e-patients have an expanded role in their own care and in larger conversations about cancer practice, research, and policy, and can be engaged as partners by healthcare professionals.
JCO ONCOLOGY PRACTICE
(2022)
Editorial Material
Oncology
Nathan A. Pennell
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Correction
Oncology
Melanie Decker, Tim Lammens, Alina Ferster, Miriam Erlacher, Ayami Yoshimi, Charlotte M. Niemeyer, Martijn P. T. Ernst, Marc H. G. P. Raaijmakers, Nicolas Duployez, Andreas Flaum, Doris Steinemann, Brigitte Schlegelberger, Thomas Illig, Tim Ripperger
Letter
Oncology
Charlotte M. Niemeyer, Martina Rudelius, Akiko Shimamura, Christian Flotho, Henrik Hasle, Elliot Stieglitz, Brigitte Strahm, Lucy A. Godley, Olga K. Weinberg, Attilio Orazi, Katherine R. Calvo
Editorial Material
Hematology
Lisa K. Hicks, Abi Vijenthira
Summary: In this article, Pagano et al present the outcomes of over 1500 patients with blood cancer and breakthrough COVID-19. Their study is significant due to its large sample size, detailed information, and relevance to the current Omicron infections.
Letter
Hematology
Amanda Przespolewski, Aaron D. Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang
Article
Biochemistry & Molecular Biology
Friedrich G. Kapp, Cedric Schneider, Annegret Holm, Hannah Glonnegger, Charlotte M. Niemeyer, Jochen Roessler, Barbara Zieger
Summary: This study analyzes the coagulation parameters of patients with vascular anomalies and finds impaired platelet aggregometry in patients with Kasabach-Merritt phenomenon and arteriovenous malformation, as well as upregulated von Willebrand factor antigen and activity in patients with complex lymphatic anomalies. These findings contribute to a better understanding of the underlying pathophysiology of these coagulopathies and may lead to new treatment options for life-threatening bleeding risks in these patients in the future.
Article
Oncology
Roshani Sinha, Mai Dvorak, Ananthakrishnan Ganesan, Larry Kalesinskas, Charlotte M. Niemeyer, Christian Flotho, Kathleen M. Sakamoto, Norman Lacayo, Rachana Vinay Patil, Rhonda Perriman, Alma-Martina Cepika, Yunying Lucy Liu, Alex Kuo, Paul J. Utz, Purvesh Khatri, Alice Bertaina
Summary: This study identifies potential druggable targets for the treatment of JMML through the analysis of DNA structures and histone modifications, providing a rich resource for improving the outcomes of JMML patients.
Article
Oncology
Ying Wu, Patricia M. A. Zehnle, Jovana Rajak, Naile Koleci, Geoffroy Andrieux, Lorena Gallego-Villar, Konrad Aumann, Melanie Boerries, Charlotte M. Niemeyer, Christian Flotho, Sheila Bohler, Miriam Erlacher
Summary: JMML cells rely on both MCL-1 and BCL-XL for survival, and azacitidine and BH3 mimetic drugs can effectively target these proteins. Azacitidine acts in vivo through downregulation of MCL-1 and upregulation of BH3-only. Combination treatment of azacitidine with BCL-XL inhibition is more effective in eliminating JMML cells compared to BCL-2 inhibition. These findings highlight the need for clinically applicable MCL-1 or BCL-XL inhibitors in JMML refractory to standard therapy.